Pharmaceutical-grade peptides & lab-use compounds available online.
Free US shipping for orders above $600
Skip to content Pharmaceutical-grade peptides & lab-use compounds available online.
Free US shipping for orders above $600
This product is intended solely for use as a research chemical in vitro and laboratory experimentation by licensed, qualified professionals.
Semaglutide is a GLP-1 receptor agonist drug approved by the FDA in June 2021 for the treatment of adult obesity. In January 2023, it was also approved for the chronic weight management of adolescents aged 12 and above. This drug achieves weight loss by delaying gastric emptying, suppressing appetite, and regulating insulin secretion.
| Specifications | Price |
|---|---|
| 1g | $1.00 |
| 10g | $10.00 |
| 1000g | $1,000.00 |
HPLS
Testing
Endotoxin
Assay
TAMC
Test
TYMC
Test
Heavy Metal
Screening
| Property | Details | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ | |||||||||||||||
| Molecular Weight | 4113.58g/mol | |||||||||||||||
| CAS Number | 910463-68-2 | |||||||||||||||
| Appearance | White Powder | |||||||||||||||
| Storage Conditions | ||||||||||||||||
| ||||||||||||||||
By activating the GLP-1 receptor, it inhibits the appetite center in the hypothalamus, reducing hunger.
It delays the gastric emptying speed and increases the feeling of fullness after eating.
It regulates insulin and glucagon secretion, improving blood sugar control, and achieving an average weight loss of 17%-18% within 68 weeks.
Treating obesity in patients with diabetes and non-diabetic patients.
Reducing the accumulation of fat on the tongue in patients with polycystic ovary syndrome.
Treating nonalcoholic steatohepatitis (NASH).
One of the first-line treatment drugs for T2DM patients with high-risk factors for atherosclerotic cardiovascular disease (ASCVD) or cardiovascular disease (CVD) as recommended by the American College of Cardiology (ACC) in 2020 and the ADA guidelines in 2022.
New clinical trials indicate that Alzheimer’s disease may become a new indication for semaglutide.
Adult trial: In the phase III clinical trial targeting obese patients, after 68 weeks of medication, the average weight loss was up to 15%-18%.
Teenager trial: The expanded indication clinical trial showed that the drug was as safe as in adults in the teenage population and had a significant weight loss effect
All product is sold solely for scientific research purposes. Researchers are responsible for ensuring compliance with local regulations and institutional guidelines. Keep out of reach of children and unauthorized personnel.
1688pharma is more than just a trusted supplier of research peptides. We are committed to scientific advancement, dedicated to providing the highest quality pharmaceutical-grade compounds that empower researchers and clients to achieve their goals.
Our proprietary processes and meticulous sourcing of premium materials ensure that every peptide we offer meets the most stringent pharmaceutical standards with verified 99% purity.
Every peptide undergoes rigorous third-party laboratory testing using advanced techniques like HPLC, LC-MS, and NMR. Complete Certificates of Analysis available for transparency and verification.
We provide expedited worldwide shipping with reliable tracking and discreet packaging. Our dedicated customer support team assists with orders, storage guidelines, and product inquiries promptly.
